Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Chande, Nilesh ^a   Tsoulis, David J ^b   Macdonald, John K ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINOSALICYCLIC ACID; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; SALICYLIC ACID; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ALLERGIC REACTION; ALLERGY; BONE MARROW SUPPRESSION; CHRONIC DISEASE; CLINICAL OUTCOME; CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; HEADACHE; HEALING; HUMAN; INFECTION; LEUKOPENIA; NAUSEA; NEOPLASM; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT RESPONSE; INDUCTION CHEMOTHERAPY; META ANALYSIS; METHODOLOGY;

6-MERCAPTOPURINE; AZATHIOPRINE; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84881273549     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000545.pub4     Document Type: Review

References (86)

1. Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator-blind study. Digestive and Liver Disease 2003;35(9):619-27.
2. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37(5):674-8.
3. Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D, et al.Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine 2010;362(15):1383-95.
4. Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D, et al.Supplementary Appendix. New England Journal of Medicine 2010;362.
5. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, et al.Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105(2):367-72.
6. Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974;66(5):916-22.
7. Mantzaris GJ, Ployzou P, Karagiannidis A, Christidou A, Koilakou S, Tsounis D, et al.A prospective, randomized trial of infliximab and azathioprine for the induction and maintenance of remission of steroid-dependent Crohn's disease. Gastroenterology 2004;126(4 Suppl 2):A54.
8. Maté-Jiménez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology 2000;12(11):1227-33.
9. Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, et al.Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. American Journal of Gastroenterology 1997;92(12):2203-9.
10. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. New England Journal of Medicine 1980;302(18):981-7.
11. Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, et al.A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. American Journal of Gastroenterology 2011;103(9):2284-92.
12. Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2(7737):1273-6.
13. Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn's disease. Gastroenterology 1979;77(4 Pt 2):898-906.
14. Singleton J, Law D, Kelley M, Mekhjian H, Sturdevant R. National Cooperative Crohn's Disease Study: Adverse Reactions to Study Drugs. Gastroenterology 1979;77(4 Pt 2):870-82.
15. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, et al.National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77(4 Pt 2):847-69.
16. Winship DH, Summers RW, Singleton JW, Best WR, Becktel JM, Lenk LF, Kern F Jr. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979;77(4 Pt 2):829-42.
17. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2(7731):944-7.
18. Chebli JMF, Gaburri PD, De Souza AFM, Pinto ALT, Chebli LA, Felga GEG, et al.Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: Open-label prospective study. Gastroenterology 2007;22:268-74.
19. Cosnes J, Bourrier A, Bouhnik Y, Laharie D, Nahon S, Bonnet J, et al.Accelerated step-care therapy with early azathioprine (AZA) vs. conventional step-care therapy in Crohn's disease. A randomized study. Gastroenterology 2012;142(5 Suppl 1):S161.
20. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al.Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7.
21. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Alimentary Pharmacology and Therapeutics 2003;18:1113-20.
22. Hinterleitner T, Petritsch W, Aichbichler B, Fickert P, Ranner G, Krejs G. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease. Zeitschrift für Gastroenterologie 1997;35(8):603-8.
23. Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, et al.Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: A randomized placebo-controlled trial. Gastroenterology 2006;130:1054-61.
24. Ludwig D, Strange EF. Efficacy of azathioprine in the treatment of chronic active Crohn's disease: prospective one-year follow-up study. German Imurek Study Group. Zeitschrift für Gastroenterologie 1999;37(11):1085-91.
25. Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflammatory Bowel Diseases 2009;15:375-82.
26. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119(4):895-902.
27. Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?. American Journal of Gastroenterology 2001;96(3):782-7.
28. Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999;44(5):625-8.
29. Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer Zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gastroenterology 1998;114(4 Pt 2):A487.
30. Reinshagen M, Schütz E, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, et al.6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clinical Chemistry 2007;53(7):1306-14.
31. Watson WC, Bukosdky M. Azathioprine in management of Crohn's disease: A randomized cross-over study. Gastroenterology 1974;66:796 (Abstract).
32. Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990;99(2):443-6.
33. Avery-Jones F, Lennard-Jones JE, Hinton JM, Reeves WG. Dangers of immuno-suppressive drugs in Ulcerative Colitis (letter). British Medical Journal 1966;1:1418.
34. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al.Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347(8996):215-9.
35. Brooke BN, Hoffmann DC, Swarbrick ET. Azathioprine for Crohn's disease. Lancet 1969;2(7621):612-4.
36. Brooke BN, Javett SL, Davison OW. Further experience with azathioprine for Crohn's disease. Lancet 1970;2(7682):1050-3.
37. Brooke BN, Cave DR, King DW. Place of azathioprine for Crohn's disease. Lancet 1976;1(7968):1041-2.
38. Brown CH, Achkar E. Azathioprine therapy for inflammatory bowel disease. A preliminary report. American Journal of Gastroenterology 1970;54(4):363-77.
39. Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. American Journal of Gastroenterology 1994;89(3):362-6.
40. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34(8):1081-5.
41. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343(8908):1249-52.
42. D'Haens G, Callens J, Hiele M, Peeters M, Rutgeerts P. Reduction of neutrophil and not lymphocyte count is associated with favourable response to azathioprine therapy in refractory Crohn's disease. Gastroenterology 1995;108:A809.
43. D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997;112(5):1475-81.
44. Drucker WR, Jeejeebhoy KN. Azathioprine: an adjunct to surgical therapy of granulomatous enteritis. Annals of Surgery 1970;172(4):618-26.
45. Fausa O, Gjone E. Azathioprine (Imurel) therapy in Crohn's disease. Acta Medica Scandinavica 1971;190(3):211-2.
46. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Alimentary Pharmacology and Therapeutics 2002;16(7):1225-32.
47. Gisbert JP, Gomollón F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. American Journal of Gastroenterology 2008;103(7):1783-800.
48. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
49. Haber CJ, Meltzer SJ, Present DH, Korelitz BI. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986;91(4):982-6.
50. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al.Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clinical Gastroenterology and Hepatology 2004;2(7):542-53.
51. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
52. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
53. Javett SL, Hoffmann VJ. Azathioprine in acute Crohn's disease. South African Medical Journal 1972;46(38):1369.
54. Kessler BH, Pettei MJ, Weinstein T, Gold DM, Levine JJ. 6-Mercaptopurine (6-MP) in pediatric Crohn's disease: high dose versus conventional dose. Gastroenterology 1995;108:A848.
55. Khan K, Dubinksky M, Ford A, Ullman T, Talley N, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel Disease: A systematic review and meta-analysis. American Journal of Gastroenterology 2011;106:630-42.
56. Korelitz BI, Present DH. Shortcomings of the National Crohn's Disease Study: the exclusion of azathioprine without adequate trial. Gastroenterology 1981;80(1):193-6.
57. Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Digestive Diseases and Sciences 1985;30(1):58-64.
58. Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. American Journal of Gastroenterology 1993;88(8):1198-205.
59. Lémann M, Bonhomme P, Bitoun A, Messing B, Modigliani R, Rambaud JC. Traitment de la maladie de Crohn par l'azathioprine ou la 6-mercaptopurine. Gastroentérologie Clinique et Biologique 1990;14(6-7):548-54.
60. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. British Journal of Clinical Pharmacology 1983;16(4):359-63.
61. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenitics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clinical Pharmacology and Therapeutics 1989;46(2):149-54.
62. Lennard L. The clinical pharmacology of 6-mercaptopurine. European Journal of Clinical Pharmacology 1992;43(4):329-39.
63. Lennard-Jones JE, Williams CB. Azathioprine in the treatment of Crohn's disease. Proceedings of the Royal Society of Medicine 1972;65:291-3.
64. Lennard-Jones JE. Azathioprine and 6-mercaptopurine have a role in the treatment of Crohn's disease. Digestive Diseases and Sciences 1981;26(4):364-8.
65. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990;99(5):1347-51.
66. Nyman M, Hansson I, Eriksson S. Long-term immunosuppressive treatment in Crohn's disease. Scandinavian Journal of Gastroenterology 1985;20(10):1197-203.
67. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991;101(1):39-46.
68. Papp JP, Watson DW, Bull FE. Azathioprine treatment in Crohn's disease. American Journal of Gastroenterology 1974;61(2):136-42.
69. Patterson JF, Norton RA, Schwartz RS. Azathioprine treatment of ulcerative colitis, granulomatous colitis and regional enteritis. American Journal of Digestive Diseases 1971;16(2):327-32.
70. Perrault J, Greseth JL, Tremaine WJ. 6-Mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn's disease. Mayo Clinic Proceedings 1991;66(5):480-4.
71. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Annals of Internal Medicine 1989;111(8):641-9.
72. Rhodes J, Bainton D, Beck P. Azathioprine in Crohn's disease. Lancet 1970;2(7683):1142.
73. Rosman M, Bertino JR. Azathioprine. Annals of Internal Medicine 1973;79(5):694-700.
74. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. European Journal of Clinical Pharmacology 2008;64:753-67.
75. Sandborn WJ, Van Os EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995;109(6):1808-17.
76. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. American Journal of Gastroenterology 1996;91(3):423-33.
77. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, et al.Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999;117(3):527-35.
78. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
79. Shah MD, Berman WF. Use of azathioprine in nine children with Crohn's disease. Virginia Medical Quarterly 1991;118(3):169-70.
80. Van Os EC, Zins BJ, Sandborn WJ, Mays DC, Tremaine WJ, Mahoney DW, et al.Azathioprine pharmacokinetics after intravenous, oral, delayed release oral, and rectal foam administration. Gut 1996;39(1):63-8.
81. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. Journal of Pediatrics 1990;117(5):809-14.
82. Wallensten S, Persson S. Azathioprine therapy for Crohn's disease. Acta Chirurgica Scandinavica 1972;138(5):521-6.
83. Weinshilboum RN, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. American Journal of Human Genetics 1980;32(5):651-62.
84. Zins BJ, Sandborn WJ, McKinney JA, Mays DC, Van Os EC, Tremaine WJ, et al.A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. Journal of Clinical Pharmacology 1997;37(1):38-46.
85. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995;123(2):132-142.
86. Prefontaine E, MacDonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2010, Issue 6. [DOI: 10.1002/14651858.CD000545.pub3]